tiprankstipranks
Trending News
More News >
Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
US Market

Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

Compare
317 Followers
See the Price Targets and Ratings of:

ZNTL Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
5 Buy
4 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Zentalis
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ZNTL Stock 12 Month Forecast

Average Price Target

$7.13
▲(369.08%Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Zentalis Pharmaceuticals in the last 3 months. The average price target is $7.13 with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 369.08% change from the last price of $1.52.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.9507692307692308,2.621538461538462,3.292307692307692,3.9630769230769234,4.633846153846154,5.304615384615385,5.975384615384615,6.6461538461538465,7.316923076923078,7.987692307692308,8.658461538461538,9.329230769230769,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.73,2.1799999999999997,2.63,3.08,3.5300000000000002,3.9799999999999995,4.43,4.88,5.33,5.78,6.2299999999999995,6.68,{"y":7.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.4892307692307694,1.6984615384615385,1.9076923076923076,2.1169230769230767,2.3261538461538462,2.5353846153846153,2.7446153846153845,2.953846153846154,3.1630769230769227,3.3723076923076922,3.581538461538462,3.7907692307692304,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.3,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.3,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.99,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.69,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.88,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$7.13Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ZNTL
Andres Y. MaldonadoH.C. Wainwright
H.C. Wainwright
$10
Buy
557.89%
Upside
Reiterated
06/02/25
Promising Phase 1 Results and Strong Efficacy Signals Drive Buy Rating for Zentalis Pharmaceuticals' Azenosertib
Leerink Partners Analyst forecast on ZNTL
Andrew BerensLeerink Partners
Leerink Partners
$5
Hold
228.95%
Upside
Reiterated
05/16/25
Cautious Outlook on Zentalis Pharmaceuticals Amid Strategic Focus and Financial Management
Wells Fargo Analyst forecast on ZNTL
Derek ArchilaWells Fargo
Wells Fargo
$6
Hold
294.74%
Upside
Reiterated
05/15/25
Zentalis Pharmaceuticals: Hold Rating Maintained Amid Lack of Short-Term Catalysts and Stock Decline
Wedbush
$4
Hold
163.16%
Upside
Reiterated
05/15/25
Oppenheimer Analyst forecast on ZNTL
Matthew BieglerOppenheimer
Oppenheimer
$10$9
Buy
492.11%
Upside
Reiterated
05/15/25
Zentalis price target lowered to $9 from $10 at OppenheimerZentalis price target lowered to $9 from $10 at Oppenheimer
Guggenheim Analyst forecast on ZNTL
Michael SchmidtGuggenheim
Guggenheim
$6
Buy
294.74%
Upside
Reiterated
05/14/25
Guggenheim Sticks to Its Buy Rating for Zentalis Pharmaceuticals (ZNTL)
TD Cowen
Buy
Initiated
05/14/25
Zentalis Pharmaceuticals: Promising Clinical Trials and Potential for Accelerated Approval Justify Buy Rating
Stifel Nicolaus Analyst forecast on ZNTL
Bradley CaninoStifel Nicolaus
Stifel Nicolaus
$9
Buy
492.11%
Upside
Reiterated
03/27/25
Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)
Morgan Stanley Analyst forecast on ZNTL
Michael UlzMorgan Stanley
Morgan Stanley
$8
Hold
426.32%
Upside
Reiterated
03/27/25
Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty
Jefferies Analyst forecast on ZNTL
Akash TewariJefferies
Jefferies
$6$2.5
Hold
64.47%
Upside
Reiterated
01/29/25
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2.50 at JefferiesJefferies analyst Akash Tewari lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $2.50 (from $6.00) while maintaining a Hold rating.
UBS
$5$2.2
Hold
44.74%
Upside
Reiterated
01/28/25
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2.20 at UBSUBS analyst Eliana Merle lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $2.20 (from $5.00) while maintaining a Neutral rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ZNTL
Andres Y. MaldonadoH.C. Wainwright
H.C. Wainwright
$10
Buy
557.89%
Upside
Reiterated
06/02/25
Promising Phase 1 Results and Strong Efficacy Signals Drive Buy Rating for Zentalis Pharmaceuticals' Azenosertib
Leerink Partners Analyst forecast on ZNTL
Andrew BerensLeerink Partners
Leerink Partners
$5
Hold
228.95%
Upside
Reiterated
05/16/25
Cautious Outlook on Zentalis Pharmaceuticals Amid Strategic Focus and Financial Management
Wells Fargo Analyst forecast on ZNTL
Derek ArchilaWells Fargo
Wells Fargo
$6
Hold
294.74%
Upside
Reiterated
05/15/25
Zentalis Pharmaceuticals: Hold Rating Maintained Amid Lack of Short-Term Catalysts and Stock Decline
Wedbush
$4
Hold
163.16%
Upside
Reiterated
05/15/25
Oppenheimer Analyst forecast on ZNTL
Matthew BieglerOppenheimer
Oppenheimer
$10$9
Buy
492.11%
Upside
Reiterated
05/15/25
Zentalis price target lowered to $9 from $10 at OppenheimerZentalis price target lowered to $9 from $10 at Oppenheimer
Guggenheim Analyst forecast on ZNTL
Michael SchmidtGuggenheim
Guggenheim
$6
Buy
294.74%
Upside
Reiterated
05/14/25
Guggenheim Sticks to Its Buy Rating for Zentalis Pharmaceuticals (ZNTL)
TD Cowen
Buy
Initiated
05/14/25
Zentalis Pharmaceuticals: Promising Clinical Trials and Potential for Accelerated Approval Justify Buy Rating
Stifel Nicolaus Analyst forecast on ZNTL
Bradley CaninoStifel Nicolaus
Stifel Nicolaus
$9
Buy
492.11%
Upside
Reiterated
03/27/25
Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)
Morgan Stanley Analyst forecast on ZNTL
Michael UlzMorgan Stanley
Morgan Stanley
$8
Hold
426.32%
Upside
Reiterated
03/27/25
Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty
Jefferies Analyst forecast on ZNTL
Akash TewariJefferies
Jefferies
$6$2.5
Hold
64.47%
Upside
Reiterated
01/29/25
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2.50 at JefferiesJefferies analyst Akash Tewari lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $2.50 (from $6.00) while maintaining a Hold rating.
UBS
$5$2.2
Hold
44.74%
Upside
Reiterated
01/28/25
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2.20 at UBSUBS analyst Eliana Merle lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $2.20 (from $5.00) while maintaining a Neutral rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zentalis Pharmaceuticals

1 Month
xxx
Success Rate
5/16 ratings generated profit
31%
Average Return
-13.08%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 31.25% of your transactions generating a profit, with an average return of -13.08% per trade.
3 Months
xxx
Success Rate
8/17 ratings generated profit
47%
Average Return
-7.99%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of -7.99% per trade.
1 Year
Matthew BieglerOppenheimer
Success Rate
1/17 ratings generated profit
6%
Average Return
-47.49%
reiterated a buy rating 26 days ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -47.49% per trade.
2 Years
xxx
Success Rate
1/17 ratings generated profit
6%
Average Return
-63.44%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 5.88% of your transactions generating a profit, with an average return of -63.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZNTL Analyst Recommendation Trends

Rating
Nov 24
Jan 25
Mar 25
May 25
Jun 25
Strong Buy
9
9
13
12
10
Buy
3
2
2
2
2
Hold
6
10
12
13
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
21
27
27
19
In the current month, ZNTL has received 12 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ZNTL average Analyst price target in the past 3 months is 7.13.
Each month's total comprises the sum of three months' worth of ratings.

ZNTL Financial Forecast

ZNTL Earnings Forecast

Next quarter’s earnings estimate for ZNTL is -$0.54 with a range of -$0.81 to -$0.43. The previous quarter’s EPS was -$0.67. ZNTL beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ZNTL has Outperformed its overall industry.
Next quarter’s earnings estimate for ZNTL is -$0.54 with a range of -$0.81 to -$0.43. The previous quarter’s EPS was -$0.67. ZNTL beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ZNTL has Outperformed its overall industry.

ZNTL Sales Forecast

Next quarter’s sales forecast for ZNTL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ZNTL beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ZNTL has Outperformed its overall industry.
Next quarter’s sales forecast for ZNTL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ZNTL beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ZNTL has Outperformed its overall industry.

ZNTL Stock Forecast FAQ

What is ZNTL’s average 12-month price target, according to analysts?
Based on analyst ratings, Zentalis Pharmaceuticals’s 12-month average price target is 7.13.
    What is ZNTL’s upside potential, based on the analysts’ average price target?
    Zentalis Pharmaceuticals has 369.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ZNTL a Buy, Sell or Hold?
          Zentalis Pharmaceuticals has a consensus rating of Moderate Buy which is based on 5 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Zentalis Pharmaceuticals’s price target?
            The average price target for Zentalis Pharmaceuticals is 7.13. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $4.00. The average price target represents 369.08% Increase from the current price of $1.52.
              What do analysts say about Zentalis Pharmaceuticals?
              Zentalis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of ZNTL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis